Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Product Type
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Plinabulin is a diketopiperazine that induces complete tubulin depolymerization in human umbilical vein endothelial cells (HUVECs) when used at a concentration of 2 μM.1 It induces HUVEC monolayer permeability, a marker of vascular collapse, in vitro. Plinabulin is cytotoxic against a panel of cancer cell lines, including the multidrug-resistant MES-SA/Dx5 and HL-60/MX2 cell lines (IC50s = 4.3-18 nM). It induces cell death in patient-derived multiple myeloma cells without affecting viability of peripheral blood mononuclear cells (PBMCs) via inhibition of tubule formation and cell migration as well as induction of mitotic arrest and apoptosis in a JNK-dependent manner.2 Plinabulin (7.5 mg/kg) reduces tumor size and increases survival in a MM.1S multiple myeloma mouse xenograft model. Formulations containing plinabulin are under clinical investigation for the treatment of solid tumors and lymphomas.
WARNING This product is not for human or veterinary use.
1. NPI-
2. A novel vascular disrupting agent plinabulin triggers JNK-